Solutions Consultant

Certara reported second quarter 2026 revenue of $93.3 million, up 1% from $92.4 million in the same period last year. The model-informed drug development company's software revenue grew 4% to $48.8 million, while services revenue declined 3% to $44.5 million. The company posted a net loss of $6.1 million, compared to net income of $1.5 million in Q2 2025. The shift primarily reflected the absence of a favourable contingent consideration adjustment from the prior year, increased currency expenses, and higher reorganisation costs. Certara completed its previously authorised $100 million share repurchase programme and received board approval for an additional $50 million buyback. The company appointed Julien Perrier as Chief Commercial Officer and reaffirmed its 2026 revenue guidance of 0% to 4% growth.

Certara (CERT) to announce earnings on Tuesday. July 28, 2026 Key points. * Certara is expected to report Q2 2026 results before the market opens Tuesday, August 4. Analysts anticipate earnings of $0.10 per share on revenue of approximately $98.1 million; full-year EPS guidance is $0.350-$0.410. * In its prior quarter, Certara reported EPS of $0.09, missing estimates of $0.11, while revenue of $106.92 million exceeded expectations and rose 0.8% year over year. * Shares recently rose 5.2% to $8.15, but Wall Street maintains a consensus "Hold" rating with an $8.85 price target. Institutional investors own approximately 74% of the stock. * Five stocks to consider instead of Certara. Certara (NASDAQ:CERT - Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $98.0870 million for the quarter. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Interested persons can find conference call details on the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET. Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.Certara's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 earnings per share. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. Certara stock up 5.2%. CERT stock traded up $0.40 during trading hours on Tuesday, reaching $8.15. 1,096,341 shares of the stock were exchanged, compared to its average volume of 3,657,619. The firm's 50-day moving average is $6.06 and its 200-day moving average is $6.62. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -81.58 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. Wall Street analysts forecast growth. Several research firms have recently weighed in on CERT. BMO Capital Markets reduced their price objective on Certara from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Tuesday, May 12th. Craig Hallum dropped their target price on Certara from $10.00 to $8.00 and set a "hold" rating on the stock in a research report on Tuesday, May 12th. Stephens cut their target price on Certara from $10.00 to $9.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 12th. Morgan Stanley reduced their price target on Certara from $11.00 to $10.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 12th. Finally, Robert W. Baird decreased their price target on shares of Certara from $7.00 to $6.00 and set a "neutral" rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $8.85. Discover more Dividend Screener Tool Hedge funds weigh in on Certara. A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC acquired a new position in shares of Certara in the fourth quarter valued at approximately $100,000. T. Rowe Price Investment Management Inc. lifted its holdings in Certara by 580,097.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company's stock worth $7,310,000 after purchasing an additional 829,540 shares during the last quarter. nVerses Capital LLC acquired a new stake in Certara during the 4th quarter worth approximately $184,000. Toronto Dominion Bank boosted its stake in Certara by 186.9% in the 4th quarter. Toronto Dominion Bank now owns 83,939 shares of the company's stock valued at $739,000 after purchasing an additional 54,677 shares during the period. Finally, Oxford Asset Management LLP bought a new stake in Certara in the 4th quarter valued at $256,000. 73.96% of the stock is owned by institutional investors. Certara company profile. Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle. The company's offerings are divided into software tools and consulting services. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Certara, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list. While Certara currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Veristat to acquire Certara's Regulatory and Medical Writing business. Strategic acquisition expands and enhances Veristat's regulatory services to help more clinical trial sponsors develop novel, life-saving therapies across complex disease areas. SOUTHBOROUGH, Mass. - April 22, 2026 - Veristat (the "Company"), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announced today its intended acquisition of Certara's Regulatory and Medical Writing business, a team known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The acquisition is supported by WindRose Health Investors, LLC, a New York-based healthcare private equity firm, which remains a partner in driving Veristat's growth trajectory and mission. Notably, the acquisition expands Veristat's regulatory writing and submission capabilities by adding more than 200 industry experts. Combined with the strong track record and market credibility of Certara's Regulatory and Medical Writing business, this strengthens Veristat's position as an industry leader uniquely equipped to help clients bring life-changing therapies to patients around the world more quickly and safely. "Over the past 30+ years, Veristat has strategically invested in organizations, people, and resources to help our clients solve their most complex clinical development, regulatory, and commercialization challenges," said Kim Boericke, Chief Executive Officer of Veristat. "By combining our complementary strengths and talented teams, Veristat will have unmatched capabilities in biostats, medical writing, and regulatory affairs, made even stronger by a shared focus on science-based insights, strong client partnerships, innovation, and impact. We will be able to bring even more life-changing medical therapies to patients with unmet needs - and that's an exciting prospect for all of us." The transaction is expected to close during the second quarter of 2026. Until then, each company will continue to operate as separate and independent entities, supporting clients as usual. About Veristat Veristat is a full-service CRO and consultancy that helps life sciences companies bring novel therapies to market fast. With 30 years of experience and support in more than 100 regulatory approvals and deep expertise in rare disease, neurological disease, oncology, and advanced therapies, Veristat integrates strategic planning, regulatory insight, and trial execution to overcome complex challenges and accelerate success. From early planning through approval, Veristat delivers tailored solutions that drive meaningful outcomes for patients worldwide. For more information, visit www.veristat.com. About Certara Certara accelerates medicines using proprietary biosimulation software, technology, and services that transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at www.certara.com. Media Contact: Lisa Barbadora, Barbadora INK for Veristat +1 (610) 420-3413 [email protected]